Medical Technologies IKC
Industry Partnership Proof of Concept Award Call

Regenerative Devices and Medical Devices with Enhanced Regenerative Functions

Graeme Howling, Jenny Spear, Jo Dixon Hardy
Medical Technologies IKC
IKC industry Partnership Proof of Concept Award

Aim of call -

• To accelerate innovation, translation and commercial development of regenerative devices, medical devices with enhanced regenerative function and related technologies

• Facilitate and support technology development towards commercialisation to achieve investment by commercial organisation
  – Take technologies from TRL 2/3 to TRL 5

• Support strong and closer collaboration between academia and medical technology industry

Proof of Concept Projects up to £100,000 will be funded in academic setting
  – (80% Full Economic Cost will be awards, 20% covered by host institution as per all RCUK grants)
Technology Readiness Levels in Medical Device Development

POC projects do not fund basic research

- It is expected basic research has been done
Scope of Call

– **Directly implanted regenerative devices**
  • scaffolds, biomaterials and devices that deliver tissue repair and regeneration
    – e.g. in Wound repair, CV, MSK, dental/max-fac, aging population

– **Enabling technologies for regenerative device development**
  • simulation methods that support development of regen devices
  • In vitro, ex vivo, in silico simulation

– **Companion technologies for regenerative device development**
  • Advanced imaging and diagnostics – earlier diagnosis, patient stratification, enhanced surgical delivery

– **Implantable medical devices with enhanced regenerative functions**
  • Conventional medical devices with added regenerative features
    – e.g. joint replacement with bioactive coating
IKC Proof of Concept Award - Overview

• **Eligibility**
  – Funded projects must be led by a UK academic institution.
  – IKC unable to directly fund industry/commercial organisations

• **Conditions**
  – Maximum duration is up to 24 months
  – Grant value up to £100k
  – Projects must have industry partnership

• **What can be supported**
  – Direct staff costs in HEI
  – Professional costs – e.g. commercial business plan development, market reports
  – Prototype development, manufacturing costs
  – Additional commercial engagement

• **What is not supported**
  – Patent costs, patent/FTO searches
Application Process

- **POC call 2 opens**
- **Expression of Interest stage**
- **EOI submission deadline**
- **POC project development phase working with IKC**
- **POC review panel**
- **POC project Awarded**

**Call opens Sept 2016**
Briefing Meeting 12 Oct 2016

**EOI deadline in 3 waves:**
- Wave 1 – 30 Nov ‘16
- Wave 2 – 31 Jan ‘17
- Wave 3 – 31 Mar ‘17

**Academic/industry/IKC co-develop full POC proposal**
Full POC proposals through to review when ready

**3 POC review panels held:**
- End March 2017
- End June 2017
- End Sept 2017
Considerations for EoI

• Vital to consider **clinical need, commercial opportunity and route to market** – even at an early stage in development pathway

• Is your development **ready for PoC funding**?
  – Where does your idea sit on the TRL scale?
  – Where do you expect to progress to with the PoC funding support?
  – Must be translational - not ‘just’ a research project
  – Show background to work done previously

• Must have an **industrial partner**
  – Develop proposal with industry input.

• Do you know how a product might be **regulated**?
EoI Hints and Tips

• Be specific about aims and objectives of the proposed project
• Tell us why project/technical solution is a good idea (under “Project Scope”) and can meet the clinical need better than existing/alternative approaches
• Tell us why the clinical need is an important one (patient numbers, expected addressable (total) market). Start to think about competitors.
• Tell us how you will protect your technology (or if IP has already been secured)
• What do you expect the next steps after this PoC project to be?
• Be specific about why this will succeed but don’t ignore the risks (and have ideas about how to mitigate these)
• Be realistic about what can be achieved
• Think about work packages and an outline Gantt chart
Project Finances

• Requested costs must be realistic and appropriate – will need to be fully described and justified in full application.

• What can be included:
  – Salaries for staff (PDRA) working directly on the project
  – Consumables – include in overall budget (headline figure at EoI stage)
  – Prototyping costs / equipment
  – Animal study costs (provided due consideration given to 3Rs)

• In line with RCUK practice, IKC will pay **80% of the Full Economic Costs**

• IKC can fund up to 6 POC projects with grant values up to £100,000
INNOVATION AND KNOWLEDGE CENTRE

• Academic team, industry partner and IKC work together to co-develop the full proposal

• Full application is more detailed than EoI – but follows pattern of EoI
  – 20 pages max
  – More detail on clinical need, commercial opportunity, route to market and technical solution.
  – Detailed project plan - Gantt chart, work packages, milestones and deliverables
  – Resource requirements including project team needed
  – Detailed financial breakdown needed
  – Risk Register –technical, commercial, financial, organisational
  – Development plan following POC funding – to commercialisation/clinic
### IKC Industry Partnership Proof of Concept Award - Timeline

<table>
<thead>
<tr>
<th>Stage</th>
<th>Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Expression of Interest proposals submission deadline - wave 1</td>
<td>5pm 30th November, 2016</td>
</tr>
<tr>
<td>Expression of Interest proposals submission deadline - wave 2</td>
<td>5pm 31st January, 2017</td>
</tr>
<tr>
<td>Expression of Interest proposals submission deadline - wave 3</td>
<td>5pm 31(^{st}) March, 2017</td>
</tr>
<tr>
<td>1st Full Application Review panel meeting</td>
<td>(tbc) end March 2017</td>
</tr>
<tr>
<td>2nd Full Application Review panel meeting</td>
<td>(tbc) end June 2017</td>
</tr>
<tr>
<td>3rd Full Application Review panel meeting</td>
<td>(tbc) end Sept 2017</td>
</tr>
<tr>
<td>Applicants informed of outcome</td>
<td>1 week after panel</td>
</tr>
</tbody>
</table>
Translational Proof of Concept Award
Further Information and Contacts

- Panel Q&A session
- Further 1 to 1 discussion today

- Key contacts:

<table>
<thead>
<tr>
<th>Contact Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Graeme Howling</td>
</tr>
<tr>
<td>Technology Innovation Manager</td>
</tr>
<tr>
<td>Technology Innovation Manager</td>
</tr>
<tr>
<td><a href="mailto:g.howling@leeds.ac.uk">g.howling@leeds.ac.uk</a></td>
</tr>
<tr>
<td>0113 343 0908</td>
</tr>
</tbody>
</table>